NASDAQ:DNLI Denali Therapeutics Q2 2025 Earnings Results & Report $17.61 -0.73 (-3.98%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$17.92 +0.32 (+1.79%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Denali Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 11, 2025. The company reported EPS of -$0.72 versus the -$0.74 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 11, 2025TimeBefore Market OpensConference Call4:00 PM ET Denali Therapeutics EPS ResultsActual EPS-$0.72Consensus EPS -$0.74Beat/MissBeat by +$0.02One Year Ago EPS-$0.59EPS Beat Rate5 of last 8 quartersDenali Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$5.64 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsDenali Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Denali Therapeutics Q2 2025 Earnings FAQ Did Denali Therapeutics beat earnings estimates for Q2 2025? Denali Therapeutics (NASDAQ:DNLI) reported earnings of -$0.72 per share for Q2 2025, beating the consensus estimate of -$0.74. The report was announced on Monday, August 11, 2025. When is Denali Therapeutics' next earnings date? Denali Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Denali Therapeutics on the company's earnings history page. Denali Therapeutics Earnings HeadlinesDenali Therapeutics (NASDAQ:DNLI) & Maze Therapeutics (NASDAQ:MAZE) Financial SurveyOctober 18 at 3:47 AM | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) and Denali Therapeutics (NASDAQ:DNLI) Head to Head ReviewOctober 12, 2026 | americanbankingnews.comBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle is set to begin by October 20. Brown has built a new model portfolio featuring five AI plays tied to this pattern, which he says has repeated with a track record of success in the past. He notes this cycle unfolds outside the traditional stock market, combined with the ongoing AI boom.October 18 at 1:00 AM | Brownstone Research (Ad)Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?October 10, 2026 | finance.yahoo.comDenali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Wall Street ZenOctober 10, 2026 | americanbankingnews.comIs Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?October 9, 2026 | finance.yahoo.comSee More Denali Therapeutics Headlines About Denali TherapeuticsDenali Therapeutics (NASDAQ:DNLI) is a biopharmaceutical company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company’s research programs address conditions involving the central nervous system, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s drug-discovery approach is built around its Transport Vehicle platform, which is designed to help therapeutic molecules cross the blood-brain barrier and reach the brain. Its pipeline has included small-molecule therapies, biologic medicines and enzyme-replacement treatments targeting disease pathways such as LRRK2, TREM2 and lysosomal dysfunction. The company advances candidates through research and clinical development and has entered into collaborations with larger pharmaceutical companies, including Biogen and Takeda. Founded in 2013, Denali is headquartered in South San Francisco, California. The company was co-founded by Ryan Watts, Ph.D., who serves as chief executive officer. Its programs are developed for potential use in global markets, with clinical research and collaborations supporting the development of treatments for patients with serious neurological and neurodegenerative conditions.View Denali Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/12 - 10/16Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?Bank of America Stock Sell-Off Looks Like a Buying OpportunityManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay SolidMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?These 2 Gold Miners Just Flashed Golden Crosses—Is a Breakout Coming? Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
